Meredith Kaya | SVP, IR & Strategic Finance |
Adam Townsend | Chief Commercial Officer |
Cedric Francois | Co-Founder, President, CEO & Director |
Timothy Sullivan | CFO & Treasurer |
Federico Grossi | Chief Medical Officer |
Madhu Kumar | Goldman Sachs Group |
Jonathan Miller | Evercore ISI |
Joseph Stringer | Needham & Company |
Philip Nadeau | Cowen and Company |
Eliana Merle | UBS |
Timur Ivannikov | Raymond James & Associates |
Derek Archila | Wells Fargo Securities |
Yigal Nochomovitz | Citigroup |
Laura Chico | Wedbush Securities |
Colleen Kusy | Robert W. Baird & Co. |
Hello, and welcome to Apellis Pharmaceuticals First Quarter 2022 Earnings Conference Call. [Operator Instructions]. It is now my pleasure to introduce Senior Vice President of Investor Relations and Strategic Finance, Meredith Kaya.
Good afternoon, and thank you for joining us to discuss Apellis's first quarter 2022 financial results. With me on the call are Co-Founder and Chief Executive Officer, Dr.